AstraZeneca COVID-19 Vaccine Trial Halt A 'Wake-Up Call,' WHO Says

Grant Boone
September 11, 2020

Chief Executive Pascal Soriot said the progress of a safety review into the trial subject will determine the timetable for vaccine progress. "Even so, I still think we are on track for having a set of data that we would submit before the end of the year (for regulatory approval)".

Mr. Soriot said manufacturing capacity for the global distribution of the vaccine should be ready by early next year, and the company intends to make the vaccine available to all regions of the world at the same time.

AstraZeneca stopped trial of Oxford vaccine, now what will happen to Corona vaccine?

Governor Rui Costa said a confidentiality agreement was signed on Tuesday to undertake the trials and Bahia will receive an initial 500 doses as soon as Brazil's health regulator Anvisa approves the protocol for testing.

3 more positive for COVID-19; county tops 100 cases per 100000
The median age of patients is 41 with the age range for infected patients from younger than 1 year old to 109 years old. An additional case required hospitalization, bringing the county's total to 24 since the beginning of the pandemic.

The U.K. study of the vaccine was paused once before, in July, according to an Oxford spokesman.

AstraZeneca CEO Pascal Soirot disclosed Wednesday that the vaccine trial was paused because a woman in the United Kingdom experienced symptoms of a rare neurological disorder called transverse myelitis.

Hundreds of thousands of people have been given two Chinese COVID-19 vaccine candidates as part of an emergency program, without a single case of infection or adverse effects, a senior official of a state-owned vaccine developer has said.

Recently, Brazil also announced that phase 3 of the clinical trials in the country for the vaccine developed by China has shown promising results.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER